

S 1906

Orphan Drug Fairness Act

Congress: 114 (2015–2017, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jul 30, 2015

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Jul 30, 2015)

Official Text: <https://www.congress.gov/bill/114th-congress/senate-bill/1906>

Sponsor

Name: Sen. Menendez, Robert [D-NJ]

Party: Democratic • **State:** NJ • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Crapo, Mike [R-ID]	R · ID		Jul 30, 2015

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Jul 30, 2015

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
114 HR 3618	Identical bill	Oct 2, 2015: Referred to the Subcommittee on Health.

Summary (as of Jul 30, 2015)

Orphan Drug Fairness Act

This bill amends the Patient Protection and Affordable Care Act (PPACA) to exclude sales of any drug or biological product approved by the Food and Drug Administration solely for rare diseases or conditions (orphan drug) from the calculation of the annual fee on manufacturers or importers with branded prescription drug sales exceeding \$5 million.

This Act is effective as if included in PPACA.

Actions Timeline

- Jul 30, 2015: Introduced in Senate
- Jul 30, 2015: Read twice and referred to the Committee on Finance

Information on this page is public domain. All other data belongs to the public.